Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 7,287 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 7,287 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the insider directly owned 18,864 shares of the company’s stock, valued at $1,735,110.72. The trade was a 27.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Joanne Quan also recently made the following trade(s):

• On Thursday, January 22nd, Joanne Quan sold 1,822 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total value of $170,047.26.
• On Tuesday, January 20th, Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $90.27, for a total value of $623,855.97.

Mirum Pharmaceuticals Stock Up 4.2%

Mirum Pharmaceuticals stock traded up $3.91 during mid-day trading on Tuesday, reaching $96.55. 865,362 shares of the company were exchanged, compared to its average volume of 830,531. The firm’s 50-day simple moving average is $95.73 and its two-hundred day simple moving average is $80.84. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $109.28. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. During the same period in the previous year, the firm posted $1.00 EPS. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. Research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on MIRM. HC Wainwright upped their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.00.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Emerald Advisers LLC boosted its stake in shares of Mirum Pharmaceuticals by 20.9% during the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after acquiring an additional 63,834 shares in the last quarter. Candriam S.C.A. increased its stake in Mirum Pharmaceuticals by 8.0% in the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after purchasing an additional 30,021 shares in the last quarter. TimesSquare Capital Management LLC acquired a new position in Mirum Pharmaceuticals during the third quarter worth $22,041,000. Y Intercept Hong Kong Ltd purchased a new stake in Mirum Pharmaceuticals during the third quarter worth $808,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in Mirum Pharmaceuticals during the third quarter worth $503,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.